Sold as Corzide. Every FDA application for this active ingredient: 1 branded and 2 generic.
As of Nov 15, 2026, FDA lists 3 applications for Bendroflumethiazide; Nadolol (sold as Corzide), first approved May 25, 1983, with 0 new uses approved and 0 published complete response letters.
| May 25, 1983 | CorzideNDA 18647 ยท New combination | King Pharms LLC | 20 | Discontinued |
| Mar 30, 2007 | Nadolol And BendroflumethiazideANDA 77833 | Impax Labs | 2 | Discontinued |
| Feb 15, 2008 | Nadolol And BendroflumethiazideANDA 78688 | Natco Pharma | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Impax Labs